Dasiprotimut T

Drug Profile

Dasiprotimut T

Alternative Names: B-cell lymphoma vaccine - Biovest; BiovaxID; Dasiprotimut-T

Latest Information Update: 05 Jun 2015

Price : $50

At a glance

  • Originator National Cancer Institute (USA)
  • Developer Biovest International; National Cancer Institute (USA)
  • Class Cancer vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Waldenstrom's macroglobulinaemia; Mantle-cell lymphoma; Follicular lymphoma
  • New Molecular Entity No
  • Available For Licensing Yes - Follicular lymphoma; Mantle-cell lymphoma

Highest Development Phases

  • Preregistration Follicular lymphoma
  • No development reported Mantle-cell lymphoma

Most Recent Events

  • 24 Apr 2015 The Committee for Medicinal Products for Human Use adopted a negative opinion for dasiprotimut T for the treatment of Follicular non-Hodgkin’s lymphoma in European Union
  • 17 Apr 2015 No recent reports of development identified - Phase-III for Follicular lymphoma (Late-stage disease) in USA, Russia and Ukraine (SC)
  • 17 Apr 2015 No recent reports of development identified - Phase-II for Mantle cell lymphoma in USA (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top